CL2011001464A1 - Compuestos derivados de purina, agonistas del receptor cb2; composicion farmaceutica que los comprende; y uso del compuesto para tratar el dolor osteoartritico. - Google Patents
Compuestos derivados de purina, agonistas del receptor cb2; composicion farmaceutica que los comprende; y uso del compuesto para tratar el dolor osteoartritico.Info
- Publication number
- CL2011001464A1 CL2011001464A1 CL2011001464A CL2011001464A CL2011001464A1 CL 2011001464 A1 CL2011001464 A1 CL 2011001464A1 CL 2011001464 A CL2011001464 A CL 2011001464A CL 2011001464 A CL2011001464 A CL 2011001464A CL 2011001464 A1 CL2011001464 A1 CL 2011001464A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- pharmaceutical composition
- receptor agonists
- derived compounds
- osteoarthritic pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Compuestos derivados de purina, agonistas del receptor cb2; composición farmacéutica que los comprende; y uso del compuesto para tratar el dolor osteoartrítico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13858908P | 2008-12-18 | 2008-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011001464A1 true CL2011001464A1 (es) | 2012-01-20 |
Family
ID=41719189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011001464A CL2011001464A1 (es) | 2008-12-18 | 2011-06-16 | Compuestos derivados de purina, agonistas del receptor cb2; composicion farmaceutica que los comprende; y uso del compuesto para tratar el dolor osteoartritico. |
Country Status (29)
Country | Link |
---|---|
US (1) | US8252798B2 (es) |
EP (1) | EP2379555B1 (es) |
JP (1) | JP5559812B2 (es) |
KR (1) | KR101319630B1 (es) |
CN (1) | CN102256977B (es) |
AR (1) | AR075104A1 (es) |
AU (1) | AU2009335997B2 (es) |
BR (1) | BRPI0923195A2 (es) |
CA (1) | CA2746740C (es) |
CL (1) | CL2011001464A1 (es) |
CO (1) | CO6390101A2 (es) |
CR (1) | CR20110340A (es) |
DO (1) | DOP2011000196A (es) |
EA (1) | EA018386B1 (es) |
EC (1) | ECSP11011151A (es) |
ES (1) | ES2536880T3 (es) |
HN (1) | HN2011001700A (es) |
IL (1) | IL213167A (es) |
MA (1) | MA32904B1 (es) |
MX (1) | MX2011006442A (es) |
NZ (1) | NZ593088A (es) |
PA (1) | PA8851501A1 (es) |
PE (1) | PE20110999A1 (es) |
SG (1) | SG172253A1 (es) |
TN (1) | TN2011000291A1 (es) |
TW (1) | TWI376378B (es) |
UA (1) | UA104010C2 (es) |
WO (1) | WO2010080306A1 (es) |
ZA (1) | ZA201103943B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2754890C (en) * | 2009-03-13 | 2018-01-16 | Piet Herdewijn | Bicyclic heterocycles |
EP2470508A1 (en) | 2009-08-28 | 2012-07-04 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
CA2793024A1 (en) * | 2010-03-17 | 2011-09-22 | F. Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
WO2011123482A1 (en) * | 2010-03-31 | 2011-10-06 | Eli Lilly And Company | Purine compounds used as cb2 agonists |
AR080711A1 (es) | 2010-03-31 | 2012-05-02 | Lilly Co Eli | Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor |
CN103209695A (zh) | 2010-09-15 | 2013-07-17 | 弗·哈夫曼-拉罗切有限公司 | 氮杂苯并噻唑化合物、组合物及应用方法 |
EP2640722B1 (en) | 2010-11-19 | 2015-11-04 | F.Hoffmann-La Roche Ag | Pyrazolopyridines and their use as tyk2 inhibitors |
WO2012116277A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
AU2012222149B2 (en) | 2011-02-25 | 2017-06-29 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
DK3395812T3 (da) | 2011-02-25 | 2022-11-28 | Arena Pharm Inc | Krystallinske former og fremgangsmåder til fremstilling af kondenserede azacykler (cannabinoid-receptor-modulatorer) |
WO2013041539A1 (en) * | 2011-09-20 | 2013-03-28 | F. Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
US9067943B2 (en) * | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
EP2885293B1 (en) * | 2012-08-16 | 2016-07-27 | Janssen Pharmaceutica, N.V. | Substituted pyrazoles as n-type calcium channel blockers |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
CA2907691A1 (en) * | 2013-05-02 | 2014-11-06 | F. Hoffmann-La Roche Ag | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists |
US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
WO2017052394A1 (en) * | 2015-09-23 | 2017-03-30 | Uniwersytet Jagielloński | Imidazopyridine compounds and their use as 5-ht6 receptor ligands |
WO2018137176A1 (en) * | 2017-01-25 | 2018-08-02 | Eli Lilly And Company | Treatment for nonalcoholic steatohepatitis and fibrosis |
WO2017181317A1 (en) * | 2016-04-18 | 2017-10-26 | Eli Lilly And Company | Treatment for nonalcoholic steatohepatitis and fibrosis |
WO2017184412A1 (en) | 2016-04-18 | 2017-10-26 | Eli Lilly And Company | Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis |
EP3558996A4 (en) * | 2016-12-21 | 2020-08-05 | Research Triangle Institute, International | DIARYLPURINE DERIVATIVES WITH IMPROVED BIOAVAILABILITY |
WO2024017227A1 (zh) * | 2022-07-21 | 2024-01-25 | 长春金赛药业有限责任公司 | 取代的稠环***素受体化合物及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60260579A (ja) * | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
US5057517A (en) * | 1987-07-20 | 1991-10-15 | Merck & Co., Inc. | Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents |
NZ225447A (en) | 1987-07-20 | 1991-12-23 | Merck & Co Inc | Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions |
GB0003960D0 (en) * | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
AU2002336462A1 (en) * | 2001-09-06 | 2003-03-24 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
US20030139427A1 (en) * | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US20050043327A1 (en) * | 2003-08-21 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
WO2005069865A2 (en) | 2004-01-13 | 2005-08-04 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
CN101044143A (zh) * | 2004-10-22 | 2007-09-26 | 辉瑞产品公司 | 制备嘌呤化合物的方法 |
US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
EP1989206B1 (en) * | 2006-02-02 | 2012-07-04 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzyme |
JP2013512245A (ja) * | 2009-11-24 | 2013-04-11 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 脂肪酸合成酵素阻害剤としてのアザベンズイミダゾール |
AR080711A1 (es) * | 2010-03-31 | 2012-05-02 | Lilly Co Eli | Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor |
-
2009
- 2009-09-12 UA UAA201107563A patent/UA104010C2/ru unknown
- 2009-12-01 AR ARP090104628A patent/AR075104A1/es not_active Application Discontinuation
- 2009-12-01 PA PA20098851501A patent/PA8851501A1/es unknown
- 2009-12-04 TW TW098141555A patent/TWI376378B/zh not_active IP Right Cessation
- 2009-12-09 PE PE2011001219A patent/PE20110999A1/es not_active Application Discontinuation
- 2009-12-09 AU AU2009335997A patent/AU2009335997B2/en not_active Ceased
- 2009-12-09 CN CN200980150689.3A patent/CN102256977B/zh not_active Expired - Fee Related
- 2009-12-09 CA CA2746740A patent/CA2746740C/en not_active Expired - Fee Related
- 2009-12-09 MX MX2011006442A patent/MX2011006442A/es active IP Right Grant
- 2009-12-09 ES ES09768474.0T patent/ES2536880T3/es active Active
- 2009-12-09 BR BRPI0923195A patent/BRPI0923195A2/pt not_active Application Discontinuation
- 2009-12-09 WO PCT/US2009/067249 patent/WO2010080306A1/en active Application Filing
- 2009-12-09 SG SG2011044773A patent/SG172253A1/en unknown
- 2009-12-09 EP EP09768474.0A patent/EP2379555B1/en not_active Not-in-force
- 2009-12-09 KR KR1020117014000A patent/KR101319630B1/ko not_active IP Right Cessation
- 2009-12-09 EA EA201170832A patent/EA018386B1/ru not_active IP Right Cessation
- 2009-12-09 JP JP2011542246A patent/JP5559812B2/ja not_active Expired - Fee Related
- 2009-12-09 US US12/633,812 patent/US8252798B2/en not_active Expired - Fee Related
- 2009-12-09 NZ NZ593088A patent/NZ593088A/xx not_active IP Right Cessation
-
2011
- 2011-05-26 IL IL213167A patent/IL213167A/en not_active IP Right Cessation
- 2011-05-27 ZA ZA2011/03943A patent/ZA201103943B/en unknown
- 2011-06-09 TN TN2011000291A patent/TN2011000291A1/fr unknown
- 2011-06-14 MA MA33947A patent/MA32904B1/fr unknown
- 2011-06-16 CL CL2011001464A patent/CL2011001464A1/es unknown
- 2011-06-17 EC EC2011011151A patent/ECSP11011151A/es unknown
- 2011-06-17 CR CR20110340A patent/CR20110340A/es unknown
- 2011-06-17 DO DO2011000196A patent/DOP2011000196A/es unknown
- 2011-06-17 HN HN2011001700A patent/HN2011001700A/es unknown
- 2011-06-23 CO CO11079298A patent/CO6390101A2/es active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011001464A1 (es) | Compuestos derivados de purina, agonistas del receptor cb2; composicion farmaceutica que los comprende; y uso del compuesto para tratar el dolor osteoartritico. | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
CL2016000495A1 (es) | Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades. | |
CO6400170A2 (es) | Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos | |
CL2008003690A1 (es) | Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos. | |
UY33379A (es) | Compuestos de morfolina | |
CL2008002521A1 (es) | Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer. | |
UY31124A1 (es) | Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842 | |
CL2008002076A1 (es) | Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades. | |
CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
ECSP11011390A (es) | Compuestos espiro-amidas sustituidas | |
ECSP11010798A (es) | 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa | |
CL2011000134A1 (es) | Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer. | |
CL2011000544A1 (es) | Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades. | |
CL2011003160A1 (es) | Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras. | |
CL2007002971A1 (es) | Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras. | |
CL2008001835A1 (es) | Uso de compuestos derivados de guaninas policiclicas para tratar la inflamacion; compuestos derivados de guanina; y compocicion farmaceutica que los comprende. | |
ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
CL2009001686A1 (es) | Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados. | |
CL2012001352A1 (es) | Compuestos heterocíclicos derivados de amina, moduladores del receptor s1p; composición farmacéutica que los comprende; uso para tratar enfermedades oculares, vasculares sistémicas inflamatorias, autoinmunitarias e inmunosupresión, cicatrización y dolor entre otras. | |
CL2007002970A1 (es) | Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras. | |
CO6351723A2 (es) | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1 | |
NI201500175A (es) | Compuestos nuevos para el tratamiento del cáncer |